CURHAN GREGORY S 4

What Happened Gregory S. Curhan, Chief Financial Officer of Serina Therapeutics (SER), was granted 123,019 derivative shares on 2026-05-21. The grant is recorded at $0.00 per share (an award/derivative instrument rather than an open‑market purchase), so no cash was exchanged at grant.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26.
• Transaction type/code: Award/Grant (derivative) — 123,019 shares at $0.00.
• Reported consideration: $0.00 (award/derivative instrument).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote (vesting): 12/48ths of the shares vest twelve months after the Vesting Commencement Date, then 1/48th vests each month thereafter until fully vested.
• No 10b5-1 plan, tax‑withholding, or cashless sale noted in the provided details.

Context This was a compensation award (likely stock options or restricted stock units subject to the stated vesting schedule), not an open‑market purchase or sale. Such grants are common for executive compensation and do not by themselves indicate immediate buying or selling of shares; vesting and any later sales would be reported in subsequent filings.